 Meridian Bioscience Inc. issued a statement Tuesday afternoon, to correct a statement made earlier regarding its SARS-CoV-2 molecular diagnostic test on its Revogene platform. The stock dropped 8.7, and has now tumbled 30.0 since it closed on Feb. 11 at the highest price since October 2008. 